Key Figures

All figures are given in millions of € according to the IFRS,
unless otherwise specified
2017 2016 2015 2014 2013 restated 2013
Order intake, sales revenue and earnings
Order intake 1,501.4 1,334.7 1,172.7 929.2 819.6 912.3
Sales revenue 1,404.6 1,300.3 1,114.8 891.2 791.6 887.3
Underlying EBITDA1) 353.2 325.4 263.2 186.8 162.3 172.6
Underlying EBITDA1) as a % of sales revenue 25.1 25.0 23.6 21.0 20.5 19.5
Relevant net profit for continuing operations2) 144.0 132.6 107.4 66.1 59.2
Relevant net profit2) 144.0 132.6 107.4 73.7 64.8 64.8
Research and development costs 68.8 59.4 52.5 43.63) 47.7 53.8
Financial data per share4)
Earnings per share, continuing operations2)
per ordinary share (in €)
2.10 1.93 1.57 0.96 0.86
per preference share (in €)
2.11 1.94 1.58 0.97 0.87
Earnings per share2)
per ordinary share (in €)
2.10 1.93 1.59 1.07 0.95 0.95
per preference share (in €)
2.11 1.94 1.60 1.08 0.96 0.96
Dividends
per ordinary share (in €)
0.505) 0.45 0.37 0.26 0.25 0.25
per preference share (in €)
0.515) 0.46 0.38 0.27 0.26 0.26
Balance sheet
Balance sheet total 2,297.7 1,753.0 1,437.2 1,273.0 1,181.3 1,176.6
Equity 806.6 736.8 644.8 497.7 450.3 450.3
Equity ratio (in %) 35.1 42.0 44.9 39.1 38.1 38.3
Financials
Capital expenditures 209.4 152.1 113.1 80.9 60.6 62.9
Capital expenditures as a % of sales 14.9 11.7 10.1 9.1 7.7 7.1
Depreciation and amortization 98.3 75.7 58.9 52.7 45.8 47.7
Net cash from operating activities 206.5 170.4 124.4 129.7 97.0 103.3
Net debt 895.5 485.9 344.0 335.66) 345.16) 345.1
Gearing (underlying) 2.5 1.5 1.3 1.76) 2.06) 2.0
Total number of employees as of December 31 7,501 6,911 6,185 5,611 5,1587) 5,8637)

1) Underlying = excluding extraordinary items

2) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result, including the corresponding tax effects for each of these items

3) Restated

4) Adjusted for stock split; rounded values

5) Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG

6) Including discontinued operation

7) Excluding TAP Biosystems